신기능 저하가 있는 노인환자에서 고혈압의 치료: 혈압목표의 설정과 약제선택에 대한 최근의 쟁점들을 중심으로
Current Controversies over the Management of Elderly Hypertension with Impaired Renal Function
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Both hypertension and aging impact renal function. Elderly patients are more likely to have chronic kidney disease (CKD),usually defined by estimated glomerular filtration rate 60 mL/min/1.73 m^2. Multiple studies over the past two decades have shown that CKD is a powerful cardiovascular disease (CVD) risk factor. Reduced kidney function in elderly people is a marker for adverse outcomes. The major goals of lowering blood pressure (BP) in patients with CKD include reduction of mortality,CVD events and slowing progression. Main considerations in the management of hypertension include selection of a target BP and selection of agents used to attain the chosen target. Current clinical practice guidelines for BP targets and choice of anti–hypertensive agents in elderly patients with CKD are not specific. Older patients with CKD might experience increased mortality and hospitalizations in association with lower baseline BP values. This review outlines controversies in applying current guidelines for the management of BP to older patients with CKD. Because of the high burden of other comorbidities in older patients with CKD, strict adherence to guidelines for the management of hypertension may not always represent the most adequate approach.
Abstract
Both hypertension and aging impact renal function. Elderly patients are more likely to have chronic kidney disease (CKD),usually defined by estimated glomerular filtration rate 60 mL/min/1.73 m^2. Multiple studies over the past two decades have shown that CKD is a powerful cardiovascular disease (CVD) risk factor. Reduced kidney function in elderly people is a marker for adverse outcomes. The major goals of lowering blood pressure (BP) in patients with CKD include reduction of mortality,CVD events and slowing progression. Main considerations in the management of hypertension include selection of a target BP and selection of agents used to attain the chosen target. Current clinical practice guidelines for BP targets and choice of anti–hypertensive agents in elderly patients with CKD are not specific. Older patients with CKD might experience increased mortality and hospitalizations in association with lower baseline BP values. This review outlines controversies in applying current guidelines for the management of BP to older patients with CKD. Because of the high burden of other comorbidities in older patients with CKD, strict adherence to guidelines for the management of hypertension may not always represent the most adequate approach.
참고문헌 (27)
- Aronow WS, "ACCF", AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension, 2011, pp.57, 2037~2114
- Kim MJ, "Renal disease in the elderly", Journal of the Korean Medical Association, 47, pp.258~267 (2004)
- Stevens LA, "CKD in the elderly--old questions and new challenges: World Kidney Day 2008", American Journal of Kidney Diseases, 51, pp.353~357 (2008)
- Gentile G, "Should we shift toward higher blood pressure targets in patients with chronic kidney disease", Journal of Nephrology, 24, pp.673~685 (2011)
- Kidney Disease Outcomes Quality Initiative (K, "DOQI)", K, American Journal of Kidney Diseases, pp.2004, 43[DOI]
- Chobanian AV, "The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report", JAMA, 289, pp.2560~2572 (2003)
- Mancia G, "2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)", Journal of Hypertension, 25, pp.1105~1187 (2007)
- Hemmelgarn BR, "Progression of kidney dysfunction in the community-dwelling elderly", Kidney International, 69, pp.2155~2161 (2006)
- O'Hare AM, "Age affects outcomes in chronic kidney disease", Journal of the American Society of Nephrology, 18, pp.2758~2765 (2007)
- O'Hare AM, "Mortality risk stratification in chronic kidney disease: one size for all ages", Journal of the American Society of Nephrology, 17, pp.846~853 (2006)
- Raymond NT, "Elevated relative mortality risk with mild-to-moderate chronic kidney disease decreases with age", Nephrology Dialysis Transplantation, 22, pp.3214~3220 (2007)
- Eriksen BO, "In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression", Kidney International, 72, pp.1242~1248 (2007)
- Gullion CM, "Impact of comorbidities on mortality in managed care patients with CKD", American Journal of Kidney Diseases, 48, pp.212~220 (2006)
- Bakris GL, "Slowing nephropathy progression: focus on proteinuria reduction", Clinical Journal of the American Society of Nephrology, 3(1), pp.S3~10 (2008)
- Onuigbo MA, "Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution", Nephron Clinical Practice, 113, pp.c63~69 (2009)
- Mann JF, "Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial", Lancet, 372, pp.547~553 (2008)
- Agodoa LY, "Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial", JAMA, 285, pp.2719~2728 (2001)
- Lewis EJ, "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group", The New England Journal of Medicine, 329, pp.1456~1462 (1993)
- Lewis EJ, "Renoprotective effect of the angiotensin- receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes", The New England Journal of Medicine, 345, pp.851~860 (2001)
- Brenner BM, "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy", The New England Journal of Medicine, 345, pp.861~869 (2001)
- Rahman M, "Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)", Archives of Internal Medicine, 165, pp.936~946 (2005)
- UK Prospective Diabetes Study Group, "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38", BMJ, 317, pp.703~713 (1998)
- Estacio RO, "The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension", The New England Journal of Medicine, 338, pp.645~652 (1998)
- Klahr S, "The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group", The New England Journal of Medicine, 330, pp.877~884 (1994)
- Wright JT Jr, "Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial", JAMA, 288, pp.2421~2431 (2002)
- Turnbull F, "Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials", BMJ, 336, pp.1121~1123 (2008)
- Turgut F, "Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations", Clinical Journal of the American Society of Nephrology, 5, pp.1330~1339 (2010)